The US Renal Disease market growth is primarily propelled by the relentless increase in the prevalence of chronic kidney disease (CKD) and its advanced stage, end-stage renal disease (ESRD). The underlying drivers of this demographic trend are the soaring rates of type 2 diabetes and hypertension, which are the two leading causes of kidney failure in the United States. As these conditions become more widespread, a larger number of individuals will inevitably progress to requiring renal care, providing a fundamental and sustained impetus for market expansion. This is compounded by the aging US population, as the incidence of CKD and ESRD is significantly higher in older adults, creating a growing patient pool that requires long-term, specialized care.

Furthermore, the market's growth is being accelerated by the continuous innovation in therapeutic and diagnostic technologies. The development of more effective pharmaceuticals for managing CKD, such as SGLT2 inhibitors and GLP-1 agonists, is expanding the market for early-stage intervention. In the late-stage segment, advancements in dialysis technology, including more efficient and user-friendly machines for both in-center and home use, are driving adoption. The growing acceptance and use of peritoneal dialysis, which allows for greater patient autonomy, is also a key growth factor. The market is also benefiting from a greater emphasis on proactive patient management, which involves integrated care models and remote monitoring to improve health outcomes and reduce costly hospitalizations. These combined factors create a robust environment for sustained market growth.